Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,315.20 +7.07 (+0.13%) Dow
39,869.54 +62.77 (+0.16%) Nasdaq
16,801.88 +7.01 (+0.04%) Bitcoin USD
70,435.57 +3,090.66 (+4.59%) CMC Crypto 200
1,524.45 +35.91 (+2.41%)
GH May 2024 17.500 put
| Previous close | 0.0400 |
| Open | 0.4500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 17.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0400 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.99k |
Business WireGuardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
PALO ALTO, Calif., May 21, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagnostic indications to identify patients who may benefit from certain targeted therapies for advanced non-sma
- Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 17, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees with a grant date
Business WireGuardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
PALO ALTO, Calif., May 16, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.
